Growth retardation in children with chronic asthma in the absence of prolonged steroid therapy

Insights

Children with chronic asthma, particularly boys, may experience lower height and weight compared to normal growth charts. This growth deficit in boys seems linked to delayed sexual maturation.

Area of Science:

  • Pediatric Endocrinology
  • Pulmonology
  • Human Growth and Development

Background:

  • Chronic asthma affects children's growth and development.
  • Previous research suggests potential links between asthma and growth retardation.
  • Understanding these effects is crucial for comprehensive patient care.

Purpose of the Study:

  • To compare height and weight of children with chronic asthma to normal growth standards.
  • To investigate potential differences in growth patterns between boys and girls with asthma.
  • To explore the relationship between asthma onset and growth outcomes.

Main Methods:

  • Height and weight measurements were collected from 380 boys and 219 girls aged 4-20 with chronic asthma.
  • Data were compared against National Center for Health Statistics (NCHS) Growth Charts.
  • Patients were not on prolonged steroid therapy.

Main Results:

  • Boys with chronic asthma showed significantly lower height (P<0.005) and weight (P<0.01) compared to NCHS norms.
  • Growth deficits in boys improved with age, reaching normal values by 19-20 years.
  • Average height percentiles for boys with early-onset asthma (0-2 years) were at the 25th percentile.
  • Girls with chronic asthma did not exhibit significant growth differences compared to norms.
  • Growth retardation in asthmatic boys appeared correlated with delayed sexual maturation.

Conclusions:

  • Chronic asthma is associated with reduced height and weight in boys, potentially linked to delayed puberty.
  • Growth patterns in asthmatic girls are not significantly impacted.
  • Early intervention and monitoring of growth in asthmatic boys may be beneficial.

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: &#946;2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...